Advertisement

Precision medicine in lupus nephritis: can biomarkers get us there?

Published:August 10, 2018DOI:https://doi.org/10.1016/j.trsl.2018.08.002
      Patients with systemic lupus erythematosus frequently develop lupus nephritis (LN), a condition that can lead to end-stage kidney disease. Multiple serum and urine biomarkers for LN have been proposed in recent years, yet none have become incorporated into clinical use. The majority of studies have been single center with significant variability in cohorts, assays, and sample storage, leading to inconclusive results. It has become clear that no single biomarker is likely to be sufficient to diagnose LN, identify flares, and define the response to therapy and prognosis. A more likely scenario is a panel of urine, serum, tissue, and genetic biomarkers. In this review, we summarize traditional and novel biomarkers and discuss how they may be utilized in order to bring precision medicine to clinical practice in LN.

      Abbreviations:

      ANA (antinuclear antibodies), Anti-dsDNA (anti–-double-stranded DNA antibodies), ESKD (end-stage kidney disease), LN (lupus nephritis), SLE (systemic lupus erythematosus)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tsokos GC
        Systemic lupus erythematosus.
        N Engl J Med. 2011; 365: 2110-2121
        • Bomback AS
        • Appel GB
        Updates on the treatment of lupus nephritis.
        J Am Soc Nephrol. 2010; 21: 2028-2035
        • Costenbader KH
        • Desai A
        • Alarcon GS
        • et al.
        Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.
        Arthritis Rheum. 2011; 63: 1681-1688
        • Sexton DJ
        • Reule S
        • Solid C
        • et al.
        ESRD from lupus nephritis in the United States, 1995-2010.
        Clin J Am Soc Nephrol. 2015; 10: 251-259
        • Parikh SV
        • Rovin BH
        Current and emerging therapies for lupus nephritis.
        J Am Soc Nephrol. 2016; 27: 2929-2939
        • Biomarkers Definitions Working G
        Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
        Clin Pharmacol Ther. 2001; 69: 89-95
        • Weening JJ
        • D'Agati VD
        • Schwartz MM
        • et al.
        The classification of glomerulonephritis in systemic lupus erythematosus revisited.
        Kidney Int. 2004; 65: 521-530
        • Yu F
        • Wu LH
        • Tan Y
        • et al.
        Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.
        Kidney Int. 2010; 77: 820-829
        • Yu F
        • Haas M
        • Glassock R
        • Zhao MH
        Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.
        Nat Rev Nephrol. 2017; 13: 483-495
        • Wu LH
        • Yu F
        • Tan Y
        • et al.
        Inclusion of renal vascular lesions in the 2003 ISN/ RPS system for classifying lupus nephritis improves renal outcome predictions.
        Kidney Int. 2013; 83: 715-723
        • Hsieh C
        • Chang A
        • Brandt D
        • et al.
        Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.
        Arthritis Care Res (Hoboken). 2011; 63: 865-874
        • Mejia-Vilet JM
        • Cordova-Sanchez BM
        • Uribe-Uribe NO
        • Correa-Rotter R
        • Morales-Buenrostro LE
        Prognostic significance of renal vascular pathology in lupus nephritis.
        Lupus. 2017; 26: 1042-1050
        • Austin 3rd, HA
        • Muenz LR
        • Joyce KM
        • Antonovych TT
        • Balow JE
        Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome.
        Kidney Int. 1984; 25: 689-695
        • Bajema IM
        • Wilhelmus S
        • Alpers CE
        • et al.
        Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
        Kidney Int. 2018; 93: 789-796
        • Malvar A
        • Pirruccio P
        • Alberton V
        • et al.
        Histologic versus clinical remission in proliferative lupus nephritis.
        Nephrol Dial Transplant. 2017; 32: 1338-1344
        • De Rosa M
        • Azzato F
        • Toblli JE
        • et al.
        A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.
        Kidney Int. 2018; ([Epub ahead of print])
        • Dall'Era M
        • Cisternas MG
        • Smilek DE
        • et al.
        Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort.
        Arthritis Rheumatol. 2015; 67: 1305-1313
        • Tamirou F
        • D'Cruz D
        • Sangle S
        • et al.
        Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.
        Ann Rheum Dis. 2016; 75: 526-531
        • Isenberg DA
        • Manson JJ
        • Ehrenstein MR
        • Rahman A
        Fifty years of anti-ds DNA antibodies: are we approaching journey's end.
        Rheumatology. 2007; 46: 1052-1056
        • Pisetsky DS
        Anti-DNA antibodies - quintessential biomarkers of SLE.
        Nat Rev Rheumatol. 2016; 12: 102-110
        • Smeenk R
        • van der Lelij G
        • Aarden L
        Avidity of antibodies to dsDNA: comparison of IFT on Crithidia luciliae, Farr assay, and PEG assay.
        J Immunol. 1982; 128: 73-78
        • Olson SW
        • Lee JJ
        • Prince LK
        • et al.
        Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis.
        Clin J Am Soc Nephrol. 2013; 8: 1702-1708
        • Mortensen ES
        • Rekvig OP
        Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes.
        J Am Soc Nephrol. 2009; 20: 696-704
        • Matrat A
        • Veysseyre-Balter C
        • Trolliet P
        • et al.
        Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares.
        Lupus. 2011; 20: 28-34
        • Julkunen H
        • Ekblom-Kullberg S
        • Miettinen A
        Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4.
        Rheumatol Int. 2012; 32: 2445-2451
        • Moroni G
        • Radice A
        • Giammarresi G
        • et al.
        Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis.
        Ann Rheum Dis. 2009; 68: 234-237
        • Yung S
        • Chan TM
        Anti-dsDNA antibodies and resident renal cells - Their putative roles in pathogenesis of renal lesions in lupus nephritis.
        Clin Immunol. 2017; 185: 40-50
        • Hanrotel-Saliou C
        • Segalen I
        • Le Meur Y
        • Youinou P
        • Renaudineau Y
        Glomerular antibodies in lupus nephritis.
        Clin Rev Allergy Immunol. 2011; 40: 151-158
        • van Bavel CC
        • Fenton KA
        • Rekvig OP
        • van der Vlag J
        • Berden JH
        Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus.
        Arthritis Rheum. 2008; 58: 1892-1899
        • Dong X
        • Zheng Z
        • Luo X
        • et al.
        Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: a case-control study.
        Medicine (Baltimore). 2018; 97: e0343
        • Zhao Z
        • Deocharan B
        • Scherer PE
        • Ozelius LJ
        • Putterman C
        Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin.
        J Immunol. 2006; 176: 7704-7714
        • Feng D
        • DuMontier C
        • Pollak MR
        The role of alpha-actinin-4 in human kidney disease.
        Cell Biosci. 2015; 5: 44
        • Mostoslavsky G
        • Fischel R
        • Yachimovich N
        • et al.
        Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry.
        Eur J Immunol. 2001; 31: 1221-1227
        • Zou X
        • Cheng H
        • Zhang Y
        • Fang C
        • Xia Y
        The antigen-binding fragment of anti-double-stranded DNA IgG enhances F-actin formation in mesangial cells by binding to alpha-actinin-4.
        Exp Biol Med. 2012; 237: 1023-1031
        • Deocharan B
        • Zhou Z
        • Antar K
        • et al.
        Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice.
        J Immunol. 2007; 179: 1313-1321
        • Becker-Merok A
        • Kalaaji M
        • Haugbro K
        • et al.
        Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
        Arthritis Res Ther. 2006; 8: R162
        • Zhang WH
        • Pan HF
        • Zhao XF
        • et al.
        Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis.
        Mol Biol Rep. 2010; 37: 1341-1345
        • Seret G
        • Canas F
        • Pougnet-Di Costanzo L
        • et al.
        Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis.
        J Autoimmun. 2015; 61: 54-61
        • Iaccarino L
        • Ghirardello A
        • Canova M
        • et al.
        Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases.
        Autoimmun Rev. 2011; 10: 553-558
        • Markoff A
        • Gerke V
        Expression and functions of annexins in the kidney.
        Am J Physiol Renal Physiol. 2005; 289: F949-F9456
        • Bonanni A
        • Vaglio A
        • Bruschi M
        • et al.
        Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference.
        Autoimmun Rev. 2015; 14: 692-702
        • Goulding NJ
        • Podgorski MR
        • Hall ND
        • et al.
        Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.
        Ann Rheum Dis. 1989; 48: 843-850
        • Bruschi M
        • Sinico RA
        • Moroni G
        • et al.
        Glomerular autoimmune multicomponents of human lupus nephritis in vivo: alpha-Enolase and Annexin AI.
        J Am Soc Nephrol. 2014; 25: 2483-2498
        • Bharadwaj A
        • Bydoun M
        • Holloway R
        • Waisman D
        Annexin A2 heterotetramer: structure and function.
        Int J Mol Sci. 2013; 14: 6259-6305
        • Yung S
        • Cheung KF
        • Zhang Q
        • Chan TM
        Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis.
        J Am Soc Nephrol. 2010; 21: 1912-1927
        • Rescher U
        • Ludwig C
        • Konietzko V
        • Kharitonenkov A
        • Gerke V
        Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion.
        Journal of cell science. 2008; 121: 2177-2185
        • Canas F
        • Simonin L
        • Couturaud F
        • Renaudineau Y
        Annexin A2 autoantibodies in thrombosis and autoimmune diseases.
        Thromb Res. 2015; 135: 226-230
        • Caster DJ
        • Korte EA
        • Merchant ML
        • et al.
        Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis.
        Proteomics Clin Appl. 2015; 9: 1012-1020
        • Cheung KF
        • Yung S
        • Chau MK
        • et al.
        Annexin II-binding immunoglobulins in patients with lupus nephritis and their correlation with disease manifestations.
        Clin Sci. 2017; 131: 653-671
        • Diaz-Ramos A
        • Roig-Borrellas A
        • Garcia-Melero A
        • Lopez-Alemany R
        alpha-Enolase, a multifunctional protein: its role on pathophysiological situations.
        J Biomed Biotechnol. 2012; 2012156795
        • Pratesi F
        • Moscato S
        • Sabbatini A
        • et al.
        Autoantibodies specific for alpha-enolase in systemic autoimmune disorders.
        J Rheumatol. 2000; 27: 109-115
        • Bruschi M
        • Carnevali ML
        • Murtas C
        • et al.
        Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens.
        J Proteomics. 2011; 74: 2008-2017
        • Papayannopoulos V
        • Zychlinsky A
        NETs: a new strategy for using old weapons.
        Trends Immunol. 2009; 30: 513-521
        • Urban CF
        • Ermert D
        • Schmid M
        • et al.
        Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans.
        PLoS Pathog. 2009; 5e1000639
        • Hakkim A
        • Furnrohr BG
        • Amann K
        • et al.
        Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.
        Proc Natl Acad Sci USA. 2010; 107: 9813-9818
        • Craft JE
        Dissecting the immune cell mayhem that drives lupus pathogenesis.
        Sci Transl Med. 2011; 3: 73ps9
        • Garcia-Romo GS
        • Caielli S
        • Vega B
        • et al.
        Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
        Sci Transl Med. 2011; 3: 73ra20
        • Lande R
        • Ganguly D
        • Facchinetti V
        • et al.
        Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.
        Sci Transl Med. 2011; 3: 73ra19
        • Villanueva E
        • Yalavarthi S
        • Berthier CC
        • et al.
        Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.
        J Immunol. 2011; 187: 538-552
        • Leffler J
        • Martin M
        • Gullstrand B
        • et al.
        Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease.
        J Immunol. 2012; 188: 3522-3531
        • Krishnan MR
        • Wang C
        • Marion TN
        Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice.
        Kidney Int. 2012; 82: 184-192
        • Jones B.
        Lupus nephritis: nucleosomes trapped by aberrantly expressed laminin-beta1.
        Nat Rev Nephrol. 2014; 10: 4
        • Olin AI
        • Morgelin M
        • Truedsson L
        • Sturfelt G
        • Bengtsson AA
        Pathogenic mechanisms in lupus nephritis: nucleosomes bind aberrant laminin beta1 with high affinity and colocalize in the electron-dense deposits.
        Arthritis Rheumatol. 2014; 66: 397-406
        • Mjelle JE
        • Rekvig OP
        • Fenton KA
        Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis.
        Ann Rheum Dis. 2007; 66: 1661-1668
        • van Bavel CC
        • van der Vlag J
        • Berden JH
        Glomerular binding of anti-dsDNA autoantibodies: the dispute resolved.
        Kidney Int. 2007; 71: 600-601
        • Kim HJ
        • Hong YH
        • Kim YJ
        • et al.
        Anti-heparan sulfate antibody and functional loss of glomerular heparan sulfate proteoglycans in lupus nephritis.
        Lupus. 2017; 26: 815-824
        • Thanei S
        • Vanhecke D
        • Trendelenburg M
        Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways.
        Clin Immunol. 2015; 160: 180-187
        • Panda AK
        • Parida JR
        • Tripathy R
        • et al.
        Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity.
        Arthritis Res Ther. 2012; 14: R218
        • Song D
        • Guo WY
        • Wang FM
        • et al.
        Complement alternative pathways activation in patients with lupus nephritis.
        Am J Med Sci. 2017; 353: 247-257
        • Thurman JM
        • Nester CM
        All things complement.
        Clin J Am Soc Nephrol. 2016; 11: 1856-1866
        • Bao L
        • Cunningham PN
        • Quigg RJ
        Complement in lupus nephritis: new perspectives.
        Kidney Dis . 2015; 1: 91-99
        • Bao L
        • Haas M
        • Quigg RJ
        Complement factor H deficiency accelerates development of lupus nephritis.
        J Am Soc Nephrol. 2011; 22: 285-295
        • Leffler J
        • Bengtsson AA
        • Blom AM
        The complement system in systemic lupus erythematosus: an update.
        Ann Rheum Dis. 2014; 73: 1601-1606
        • Luijten KM
        • Tekstra J
        • Bijlsma JW
        • Bijl M
        The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.
        Autoimmun Rev. 2012; 11: 326-329
        • Mikdashi J
        • Nived O
        Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.
        Arthritis Res Ther. 2015; 17: 183
      1. Esdaile JM, Joseph L, Abrahamowicz M, et al. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol. 1996;23:1891–6.

        • Ricker DM
        • Hebert LA
        • Rohde R
        • et al.
        Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group.
        Am J Kidney Dis. 1991; 18: 678-685
        • Ho A
        • Barr SG
        • Magder LS
        • Petri M
        A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
        Arthritis Rheum. 2001; 44: 2350-2357
        • Birmingham DJ
        • Irshaid F
        • Nagaraja HN
        • et al.
        The complex nature of serum C3 and C4 as biomarkers of lupus renal flare.
        Lupus. 2010; 19: 1272-1280
        • Thielens NM
        • Tedesco F
        • Bohlson SS
        • Gaboriaud C
        • Tenner AJ
        C1q: a fresh look upon an old molecule.
        Mol Immunol. 2017; 89: 73-83
        • Macedo AC
        • Isaac L
        Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway.
        Front Immunol. 2016; 7: 55
        • Orbai AM
        • Truedsson L
        • Sturfelt G
        • et al.
        Anti-C1q antibodies in systemic lupus erythematosus.
        Lupus. 2015; 24: 42-49
        • Yang XW
        • Tan Y
        • Yu F
        • Zhao MH
        Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis.
        Nephrol Dial Transplant. 2012; 27: 3552-3559
        • Bock M
        • Heijnen I
        • Trendelenburg M
        Anti-C1q antibodies as a follow-up marker in SLE patients.
        PLoS One. 2015; 10e0123572
        • Fatemi A
        • Samadi G
        • Sayedbonakdar Z
        • Smiley A
        Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study.
        Mod Rheumatol. 2016; 26: 233-239
        • Wang Y
        • Hu Q
        • Madri JA
        • et al.
        Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
        Proc Natl Acad Sci USA. 1996; 93: 8563-8568
        • Wang S
        • Wu M
        • Chiriboga L
        • Zeck B
        • Belmont HM
        Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment.
        Semin Arthritis Rheum. 2018; ([Epub ahead of print])
        • Mahler M
        • van Schaarenburg RA
        • Trouw LA
        Anti-C1q autoantibodies, novel tests, and clinical consequences.
        Front Immunol. 2013; 4: 117
        • Papp K
        • Vegh P
        • Hobor R
        • et al.
        Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays.
        PLoS One. 2012; 7: e44824
        • Sciascia S
        • Radin M
        • Yazdany J
        • et al.
        Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
        Rheumatol Int. 2017; 37: 1249-1255
        • Martensson J
        • Bellomo R
        The rise and fall of NGAL in acute kidney injury.
        Blood Purif. 2014; 37: 304-310
        • Suzuki M
        • Wiers KM
        • Klein-Gitelman MS
        • et al.
        Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis.
        Pediatr Nephrol . 2008; 23: 403-412
        • Rubinstein T
        • Pitashny M
        • Levine B
        • et al.
        Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.
        Rheumatology. 2010; 49: 960-971
        • Satirapoj B
        • Kitiyakara C
        • Leelahavanichkul A
        • Avihingsanon Y
        • Supasyndh O
        Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis.
        BMC Nephrol. 2017; 18: 263
        • Kulkarni O
        • Pawar RD
        • Purschke W
        • et al.
        Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.
        J Am Soc Nephrol. 2007; 18: 2350-2358
        • Gupta R
        • Yadav A
        • Aggarwal A
        Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.
        Clin Rheumatol. 2016; 35: 2707-2714
        • Rovin BH
        • Song H
        • Birmingham DJ
        • et al.
        Urine chemokines as biomarkers of human systemic lupus erythematosus activity.
        J Am Soc Nephrol. 2005; 16: 467-473
        • Singh RG
        • Usha RathoreSS
        • Behura SK
        • Singh NK
        Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare.
        Lupus. 2012; 21: 1214-1218
        • Kaplan MJ
        • Lewis EE
        • Shelden EA
        • et al.
        The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells.
        J Immunol. 2002; 169: 6020-6029
        • Michaelson JS
        • Wisniacki N
        • Burkly LC
        • Putterman C
        Role of TWEAK in lupus nephritis: a bench-to-bedside review.
        J Autoimmun. 2012; 39: 130-142
        • Schwartz N
        • Su L
        • Burkly LC
        • et al.
        Urinary TWEAK and the activity of lupus nephritis.
        J Autoimmun. 2006; 27: 242-250
        • Xuejing Z
        • Jiazhen T
        • Jun L
        • et al.
        Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases.
        J Biomed Biotechnol. 2012; 2012359647
        • Zhao Z
        • Burkly LC
        • Campbell S
        • et al.
        TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus.
        J Immunol. 2007; 179: 7949-7958
        • Molano A
        • Lakhani P
        • Aran A
        • et al.
        TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis.
        Immunol Lett. 2009; 125: 119-128
        • Xia Y
        • Campbell SR
        • Broder A
        • et al.
        Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.
        Clin Immunol. 2012; 145: 108-121
        • Almaani S
        • Hebert LA
        • Rovin BH
        • Birmingham DJ
        The urine preservative acetic acid degrades urine protein: implications for urine biorepositories and the AASK cohort study.
        J Am Soc Nephrol. 2017; 28: 1394-1398
        • Zhang X
        • Nagaraja HN
        • Nadasdy T
        • et al.
        A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies.
        Kidney Int. 2012; 81: 401-406
        • Abulaban KM
        • Song H
        • Zhang X
        • et al.
        Predicting decline of kidney function in lupus nephritis using urine biomarkers.
        Lupus. 2016; 25: 1012-1018
        • Baker C
        • Belbin O
        • Kalsheker N
        • Morgan K
        SERPINA3 (aka alpha-1-antichymotrypsin).
        Front Biosci. 2007; 12: 2821-2835
        • Aggarwal A
        • Gupta R
        • Negi VS
        • et al.
        Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis.
        Clin Exp Immunol. 2017; 188: 254-262
        • Bombardier C
        • Gladman DD
        • Urowitz MB
        • Caron D
        • Chang CH
        Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.
        Arthritis Rheum. 1992; 35: 630-640
        • Wolf BJ
        • Spainhour JC
        • Arthur JM
        • et al.
        Development of biomarker models to predict outcomes in lupus nephritis.
        Arthritis Rheumatol. 2016; 68: 1955-1963
        • Rovin BH
        • Furie R
        • Latinis K
        • et al.
        Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
        Arthritis Rheum. 2012; 64: 1215-1226
        • Pencina MJ
        • D'Agostino Sr., RB
        • Demler OV
        Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models.
        Stat Med. 2012; 31: 101-113
        • Grund B
        • Sabin C
        Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.
        Curr Opin HIV AIDS. 2010; 5: 473-479
      2. Administration USFaD. FDA/CDER Biomarker Qualification Program. 2009.

        • Kitagori K
        • Yoshifuji H
        • Oku T
        • et al.
        Cleaved form of osteopontin in urine as a clinical marker of lupus nephritis.
        PLoS One. 2016; 11e0167141
        • Wei R
        • Gao B
        • Shih F
        • et al.
        Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology.
        Nephrol Dial Transplant. 2017; 32: 1468-1477
        • Birmingham DJ
        • Merchant M
        • Waikar SS
        • et al.
        Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.
        Nephrol Dial Transplant. 2017; 32: i71-i91
        • Bartel DP.
        MicroRNAs: genomics, biogenesis, mechanism, and function.
        Cell. 2004; 116: 281-297
        • Merchant ML
        • Rood IM
        • Deegens JKJ
        • Klein JB
        Isolation and characterization of urinary extracellular vesicles: implications for biomarker discovery.
        Nat Rev Nephrol. 2017; 13: 731-749
        • Cardenas-Gonzalez M
        • Srivastava A
        • Pavkovic M
        • et al.
        Identification, confirmation, and replication of novel urinary MicroRNA biomarkers in lupus nephritis and diabetic nephropathy.
        Clin Chem. 2017; 63: 1515-1526
        • Olivares D
        • Perez-Hernandez J
        • Forner MJ
        • et al.
        Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis.
        Clin Sci. 2018; 132: 569-579
        • Hu N
        • Long H
        • Zhao M
        • Yin H
        • Lu Q
        Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice.
        Scand J Rheumatol. 2009; 38: 464-471
        • Ikuma D
        • Hiromura K
        • Kajiyama H
        • et al.
        The correlation of urinary podocytes and podocalyxin with histological features of lupus nephritis.
        Lupus. 2018; 27: 484-493
        • Lindqvist AK
        • Alarcon-Riquelme ME
        The genetics of systemic lupus erythematosus.
        Scand J Immunol. 1999; 50: 562-571
        • Su K
        • Wu J
        • Edberg JC
        • et al.
        A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus.
        J Immunol. 2004; 172: 7186-7191
        • Graham RR
        • Cotsapas C
        • Davies L
        • et al.
        Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus.
        Nat Genet. 2008; 40: 1059-1061
        • Graham RR
        • Kyogoku C
        • Sigurdsson S
        • et al.
        Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus.
        Proc Natl Acad Sci USA. 2007; 104: 6758-6763
        • Sanchez E
        • Palomino-Morales RJ
        • Ortego-Centeno N
        • et al.
        Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus.
        Hum Mol Genet. 2009; 18: 3739-3748
        • Han S
        • Kim-Howard X
        • Deshmukh H
        • et al.
        Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE).
        Hum Mol Genet. 2009; 18: 1171-1180
        • Nishimoto K
        • Kochi Y
        • Ikari K
        • et al.
        Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.
        Ann Rheum Dis. 2010; 69: 368-373
        • Harley IT
        • Kaufman KM
        • Langefeld CD
        • Harley JB
        • Kelly JA
        Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies.
        Nat Rev Genet. 2009; 10: 285-290
        • Gateva V
        • Sandling JK
        • Hom G
        • et al.
        A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.
        Nat Genet. 2009; 41: 1228-1233
        • Han JW
        • Zheng HF
        • Cui Y
        • et al.
        Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus.
        Nat Genet. 2009; 41: 1234-1237
        • Heyninck K
        • Beyaert R
        A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions.
        Trends Biochem Sci. 2005; 30: 1-4
        • Mauro C
        • Pacifico F
        • Lavorgna A
        • et al.
        ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB.
        J Biol Chem. 2006; 281: 18482-18488
        • Verstrepen L
        • Carpentier I
        • Verhelst K
        • Beyaert R
        ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.
        Biochem Pharmacol. 2009; 78: 105-114
        • Wagner S
        • Carpentier I
        • Rogov V
        • et al.
        Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins.
        Oncogene. 2008; 27: 3739-3745
        • Nanda SK
        • Venigalla RK
        • Ordureau A
        • et al.
        Polyubiquitin binding to ABIN1 is required to prevent autoimmunity.
        J Exp Med. 2011; 208: 1215-1228
        • Caster DJ
        • Korte EA
        • Nanda SK
        • et al.
        ABIN1 Dysfunction as a genetic basis for Lupus Nephritis.
        J Am Soc Nephrol. 2013; 24: 1743-1754
        • Korte EA
        • Caster DJ
        • Barati MT
        • et al.
        ABIN1 Determines Severity of Glomerulonephritis via Activation of Intrinsic Glomerular Inflammation.
        Am J Pathol. 2017; 187: 2799-2810
        • Adrianto I
        • Wen F
        • Templeton A
        • et al.
        Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus.
        Nat Genet. 2011; 43: 253-258
        • Yang W
        • Zhao M
        • Hirankarn N
        • et al.
        ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai.
        Hum Mol Genet. 2009; 18: 2063-2070
        • Kim-Howard X
        • Maiti AK
        • Anaya JM
        • et al.
        ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry.
        Ann Rheum Dis. 2010; 69: 1329-1332
        • Sanchez E
        • Nadig A
        • Richardson BC
        • et al.
        Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.
        Ann Rheum Dis. 2011; 70: 1752-1757
        • Li LH
        • Yuan H
        • Pan HF
        • et al.
        Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis.
        Scand J Rheumatol. 2010; 39: 148-154
        • Bates JS
        • Lessard CJ
        • Leon JM
        • et al.
        Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations.
        Genes Immun. 2009; 10: 470-477
        • Lin CP
        • Adrianto I
        • Lessard CJ
        • et al.
        Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.
        Genes Immun. 2012; 13: 232-238
        • Zhou XJ
        • Cheng FJ
        • Qi YY
        • Zhao MH
        • Zhang H
        A replication study from Chinese supports association between lupus-risk allele in TNFSF4 and renal disorder.
        Biomed Res Int. 2013; 2013597921
        • Freedman BI
        • Langefeld CD
        • Andringa KK
        • et al.
        End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.
        Arthritis Rheumatol. 2014; 66: 390-396
        • Munroe ME
        • James JA
        Genetics of lupus nephritis: clinical implications.
        Semin Nephrol. 2015; 35: 396-409
        • Iwamoto T
        • Niewold TB
        Genetics of human lupus nephritis.
        Clin Immunol. 2017; 185: 32-39
        • Korte EA
        • Caster DJ
        • Barati MT
        • et al.
        ABIN1 Determines severity of glomerulonephritis via activation of intrinsic glomerular inflammation.
        Am J Pathol. 2017; 187: 2799-2810
        • Beck Jr., LH
        • Bonegio RG
        • Lambeau G
        • et al.
        M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
        N Eng J Med. 2009; 361: 11-21
        • Stanescu HC
        • Arcos-Burgos M
        • Medlar A
        • et al.
        Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.
        N Eng J Med. 2011; 364: 616-626
        • Li Y
        • Zhou A
        • Lv G
        • et al.
        Single-nucleotide polymorphisms in the PLA2R1 gene are associated with systemic lupus erythematosus and lupus nephritis in a Chinese Han population.
        Immunol Res. 2016; 64: 324-348
        • Almlof JC
        • Alexsson A
        • Imgenberg-Kreuz J
        • et al.
        Novel risk genes for systemic lupus erythematosus predicted by random forest classification.
        Sci Rep. 2017; 7: 6236